CRVO_OUT_1 [2025-04-04 09:50:15 -0400] 3511 Bytes | 1026 tokens | Cum: 1026 tkns (12.83% of 8k)
==========================================================================

Booyah, my friends! It's already 9:50:15 AM on Fri Apr 04, 2025 -0400, and I've got my eyes locked on CervoMed (CRVO), pushing up to 13.0201 from 11.24. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: CervoMed (CRVO)
IPO: 1996-06-18 (28 Years Ago)
Market Cap: $86,853,136
Shares Outstanding: 8,700,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Here’s the first list of news for CervoMed:

C1 - Apr-02-25 07:00AM - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025
C2 - Mar-31-25 02:34PM - Biotech Stocks Q1 2025 Recap: Winners And Underperformers
C3 - Mar-25-25 08:00AM - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD )
C4 - Mar-22-25 11:00AM - Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings
C5 - Mar-22-25 11:00AM 02:55AM - CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
C6 - Mar-19-25 04:27PM - Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?
C7 - Mar-18-25 04:48AM - CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now
C8 - Mar-17-25 08:00AM - CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

Prior AI Reports for CRVO:
1. 2025-04-02 – Score: 1 – Target: 12.5550 – Highs: 14.0000 / 13.3499 / –
high-performance-marred-by-negative-returns-and-instability
2. 2025-03-27 – Score: 50 – Target: 11.2800 – Highs: 10.7200 / 9.6865 / 10.07
high-sales-growth-amid-negative-returns-sparks-uncertainty
3. 2025-03-21 – Score: 85 – Target: 21.6000 – Highs: 16.9400 / 14.9678 / 10.53
cervomed-incs-skyrocketing-sales-signal-bullish-market-trend
4. 2025-03-20 – Score: 65 – Target: 13.2500 – Highs: 12.2700 / 16.9400 / 14.97
cervomeds-strong-growth-tempered-by-market-skepticism

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: CervoMed (CRVO).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

CRVO_OUT_3 [2025-04-04 09:50:24 -0400] 1099 Bytes | 322 tokens | Cum: 1351 tkns (16.89% of 8k)
==========================================================================

Showing C1 (chunk 1 of 13): C1:
**Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025**
Date: Apr-02-25 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/02/3054108/0/en/Investigators-to-Present-Clinical-Trial-Results-Showing-Neflamapimod-Slows-Clinical-Progression-in-Dementia-with-Lewy-Bodies-in-Oral-Presentation-at-AD-PD-2025.html

April 02, 2025 07:00 ET| Source:CervoMed Inc.CervoMed Inc.

During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC)

Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at A

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_5 [2025-04-04 09:50:25 -0400] 1004 Bytes | 284 tokens | Cum: 1768 tkns (22.10% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T17:06:22Z - 11 Health Care Stocks Moving In Thursday's Intraday Session - Aldeyra Therapeutics (NASDAQ:ALDX), Ap...
A2 - 2025-04-03T05:03:54Z - CervoMed (CRVO) Expected to Announce Quarterly Earnings on Friday...
A3 - 2025-04-02T11:33:26Z - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in D...
A4 - 2025-04-02T11:28:03Z - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in D...
A5 - 2025-04-02T11:19:10Z - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in D...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CRVO_OUT_7 [2025-04-04 09:50:26 -0400] 1098 Bytes | 338 tokens | Cum: 2108 tkns (26.35% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**11 Health Care Stocks Moving In Thursday's Intraday Session - Aldeyra Therapeutics (NASDAQ:ALDX), Aptevo Therapeutics (NASDAQ:APVO)**Date: 2025-04-03Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44632127/11-health-care-stocks-moving-in-thursdays-intraday-sessionGainers Protagenic Therapeutics PTIX shares rose 85.8% to $0.42 during Thursday's regular session. The market value of their outstanding shares is at $3.0 million. As per the news, the Q4 earnings report came out 3 days ago. OSR Holdings OSRH shares moved upwards by 59.18% to $2.34. The market value of their outstanding shares is at $45.1 million. Aptevo Therapeutics APVO shares rose 45.67% to $2.01. The company's market cap stands at $2.9 million. Alaunos Therapeutics TCRT shares rose 38.75% to $3.88. The market value of their outstanding shares i

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_9 [2025-04-04 09:50:27 -0400] 1026 Bytes | 308 tokens | Cum: 2418 tkns (30.23% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-29T13:00:00Z - CervoMed to Present at the 8th International Lewy Body Dementia Conference
B2 - 2024-10-02T12:00:00Z - CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
B3 - 2024-06-11T12:00:00Z - CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
B4 - 2024-04-08T12:00:36Z - Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
B5 - 2024-04-01T12:00:00Z - CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
B6 - 2024-03-28T12:30:00Z - CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRVO_OUT_11 [2025-04-04 09:50:30 -0400] 681 Bytes | 214 tokens | Cum: 2634 tkns (32.92% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/11/2896702/0/en/CervoMed-Announces-Completion-of-Enrollment-in-Phase-2b-RewinD-LB-Clinical-Trial-of-Neflamapimod-for-the-Treatment-of-Patients-with-Dementia-with-Lewy-Bodies.html- Topline data expected in December 2024 -

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_13 [2025-04-04 09:50:31 -0400] 1100 Bytes | 308 tokens | Cum: 2997 tkns (37.46% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

S2 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

S3 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRVO_OUT_15 [2025-04-04 09:50:40 -0400] 1041 Bytes | 265 tokens | Cum: 3264 tkns (40.80% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference.

The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_17 [2025-04-04 09:50:52 -0400] 4809 Bytes | 1338 tokens | Cum: 4759 tkns (59.49% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+------------------------+
| Volume: 147,259 | Perf Month: 493.80% | Option/Short: No / Yes | Sales Y/Y TTM: 142.42% |
+-------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 4.69M | Perf Quarter: 472.50% | Short Float: 46.70% | ROE: -69.95% |
+-------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.50 | Index: RUT | Short Ratio: 0.56 | ROI: -41.56% |
+-------------------+-----------------------+------------------------+------------------------+
| RSI (14): 64.43 | Market Cap: 111.11M | Short Interest: 2.63M | Sales Surprise: 40.76% |
+-------------------+-----------------------+------------------------+------------------------+
| ATR (14): 1.95 | Shs Outstand: 8.70M | Beta: -0.32 | EPS Surprise: -24.55% |
+-------------------+-----------------------+------------------------+------------------------+
| SMA20: 43.00% | Shs Float: 5.64M | Sales Q/Q: -13.19% | P/E: - |
+-------------------+-----------------------+------------------------+------------------------+
| SMA50: 160.07% | Inst Own: 17.08% | Sales past 5Y: 7.26% | Earnings: Mar 17 BMO |
+-------------------+-----------------------+------------------------+------------------------+
| SMA200: 24.95% | Insider Own: 35.20% | Employees: 15 | |
+-------------------+-----------------------+------------------------+------------------------+
| Perf Week: 34.67% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+-------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading if any are accessible.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 9737974.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -16290695.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 12.9126
Average Volume: 12275442.7
30-Day High: 14.29
30-Day Low: 2.15

[Detailed Financials: TTM 2024]
- Total Assets: $43,081,610.0
- Total Liabilities: $3,879,282.0
- Total Equity: $39,202,328.0
- Current Assets: $43,081,610.0
- Current Liabilities: $3,879,282.0

[Income Statement: TTM 2024]
- Revenue: $9,737,974.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,206,650.0

[Detailed Financials: FY 2024]
- Total Assets: $43,081,610.0
- Total Liabilities: $3,879,282.0
- Total Equity: $39,202,328.0
- Current Assets: $43,081,610.0
- Current Liabilities: $3,879,282.0

[Income Statement: FY 2024]
- Revenue: $9,737,974.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,206,650.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

CRVO_OUT_19 [2025-04-04 09:50:53 -0400] 687 Bytes | 169 tokens | Cum: 5141 tkns (64.26% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

CRVO_IN_21 [2025-04-04 09:50:54 -0400] 126 Bytes | 29 tokens | Cum: 5200 tkns (65.00% of 8k)
==========================================================================

====================================
[2025-04-04 09:50:54] # Analysis Completed
Elapsed Time: 39.37 seconds